Identiv, Inc. Files Q3 2024 10-Q Report

TL;DR

Identiv's Q3 10-Q is in. Check financials.

AI Summary

Identiv, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter. Key financial data and disclosures relevant to investors are presented.

Why It Matters

This report provides investors with the latest financial health and operational performance of Identiv, Inc., crucial for making informed investment decisions.

Risk Assessment

Risk Level: medium — 10-Q filings are standard financial reports, but the specific content can reveal risks or opportunities impacting the company's future.

Key Numbers

• N/A — Revenue (Specific revenue figures for Q3 2024 are not directly extractable from the provided header information.)
• N/A — Net Income (Specific net income figures for Q3 2024 are not directly extractable from the provided header information.)
• N/A — Earnings Per Share (Specific EPS figures for Q3 2024 are not directly extractable from the provided header information.)

Key Players & Entities

• Identiv, Inc. (company) — Filer
• 2024-09-30 (date) — Reporting Period End Date
• 2024-11-12 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share INVE The Nasdaq

Filing Documents

• inve-20240930.htm (10-Q) — 2318KB
• inve-ex10_1.htm (EX-10.1) — 83KB
• inve-ex31_1.htm (EX-31.1) — 14KB
• inve-ex31_2.htm (EX-31.2) — 14KB
• inve-ex32.htm (EX-32) — 12KB
• 0000950170-24-125344.txt ( ) — 10507KB
• inve-20240930.xsd (EX-101.SCH) — 1588KB
• inve-20240930_htm.xml (XML) — 1979KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Comprehensive Income (Loss) 4 Condensed Consolidated Statements of Stockholders' Equity 5 Condensed Consolidated Statements of Cash Flows 7 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 4.

Controls and Procedures

Controls and Procedures 30

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35 Item 5. Other Information 35 Item 6. Exhibits 36

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION

Fin ancial Statements

Item 1. Fin ancial Statements IDENTIV, INC. CONDENSED CONSOLIDA TED BALANCE SHEETS (Unaudited, in thousands, except par value) September 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 145,361 $ 23,312 Restricted cash 384 1,072 Accounts receivable, net of allowances of $ 622 and $ 1,610 as of September 30, 2024 and December 31, 2023, respectively 4,848 7,404 Inventories 10,710 13,560 Prepaid expenses and other current assets 4,700 1,222 Current assets held-for-sale — 32,916 Total current assets 166,003 79,486 Property and equipment, net 8,203 8,472 Operating lease right-of-use assets 2,110 2,289 Other assets 713 678 Non-current assets held-for-sale — 18,798 Total assets $ 177,029 $ 109,723 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 6,035 $ 4,652 Financial liabilities, net of debt issuance costs of $ 0 and $ 51 as of September 30, 2024 and December 31, 2023, respectively — 9,949 Operating lease liabilities 880 782 Accrued compensation and related benefits 1,321 1,376 Accrued income taxes payable 7,180 104 Other accrued expenses and liabilities 3,595 917 Current liabilities held-for-sale — 13,002 Total current liabilities 19,011 30,782 Long-term operating lease liabilities 1,251 1,507 Other long-term liabilities 27 26 Non-current liabilities held-for-sale — 3,136 Total liabilities 20,289 35,451 Commitments and contingencies (see Note 15) Stockholders' equity: Preferred stock, $ 0.001 par value: 10,000 shares authorized; 5,000 shares issued and outstanding as of September 30, 2024 and December 31, 2023 5 5 Common stock, $ 0.001 par value: 50,000 shares authorized; 25,941 and 24,902 shares issued and 23,873 and 23,247 shares outstanding as of September 30, 2024 and December 31, 2023, respectively 26 25 Additional pa

View Full Filing

View this 10-Q filing on SEC EDGAR